Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Bisacodyl

Unchecked
From Pharmacopedia
Bisacodyl
Dulcolax, Correctol, Bisac-Evac

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Common uses
Acute or short-term constipation0, Bowel preparation before colonoscopy (with PEG)0
Pharmacy
Starting dose
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses
Preparations
5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx
US FDA Max
30 mg/d for short-term use
Pharmacology
Routes
Oral, rectal
Onset
PO 6-12 hours; PR 15-60 minutes
Duration
Hours
Half-life
Variable; effect dependent on local intestinal action rather than systemic kinetics[1]
Bioavailability
Low systemic absorption (enteric coating delivers drug to colon)[1]
Pregnancy
Generally considered acceptable for short-term use.[citation needed]
Legal status
OTC in US
Purported mechanism
Bisacodyl is a diphenylmethane stimulant laxative hydrolyzed by intestinal enzymes to its active form, which directly stimulates the colonic enteric nervous system to increase peristalsis and induces water and electrolyte secretion into the lumen.0 Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses[1].

References

edit
  1. 1.0 1.1 1.2 FDA OTC monograph for bisacodyl, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020716s029lbl.pdf